Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
02/14/2023 - 04:05 PM
TEMPLE CITY, Calif. --(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday, February 28, 2023 . Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT ) to discuss the results and answer questions.
The call may be accessed through a live audio webcast on the Investor Relations section of the company’s website, http://ir.fulgentgenetics.com . An audio replay will be available at the same location.
About Fulgent
Fulgent is a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology. Its proprietary technology platform for genetics has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Fulgent’s therapeutics business is fully focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology.
View source version on businesswire.com : https://www.businesswire.com/news/home/20230214005675/en/
Investor Relations Contact:
The Blueshirt Group
Melanie Solomon , melanie@blueshirtgroup.com
Source: Fulgent Genetics, Inc.
FLGT Rankings
#4291 Ranked by Stock Gains
FLGT Stock Data
Industry
Dental Laboratories
Sector
Manufacturing
Tags
Health Services, Medical/Nursing Services, Manufacturing, Dental Laboratories
Country
US
City
Temple City
About FLGT
mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques
